- On December 21, 2021, Cassava Sciences Trading was halted two times.
- Whether intentional or unintentional, the SEC facilitated and unjustly enriched shorts, by preventing the price-per-share from rising to pre-market levels.
- If Cassava Sciences is being investigated by the SEC, the SEC must conclude this investigation and allow the market to function without interference.
Cassava Sciences, Inc. (SAVA) enjoyed two trading halts on December 21, 2021, as follows:
Whether intentional or unintentional, these trading halts unjustly enriched shorts, by preventing a “short squeeze.”
The Securities and Exchange Commission [SEC] did not intervene and prevent SAVA stock from dropping when the brilliantly orchestrated “short and distort” was executed, beginning with the Citizen’s Petition [CP] filed with the Food & Drug Administration [FDA], and they should, also, not interfere with a meteoric rise in the firm’s stock or price-per-share when good news is released.
Effectively, the SEC assisted those with short positions and harmed those with long positions in Cassava Sciences stock. If the SEC is investigating Cassava Sciences for shorting their own stock, they must conclude this investigation, publicly announce the conclusion of this investigation, and avoid any further actions that only continue to unjustly enrich those involved in the “short and distort” activities surrounding the price-per-share of Cassava Sciences stock.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.